Implementation of Long-Acting PrEP: Case-Based Panel Discussion With Clinicians (On-Demand)
Assessment of Needs
This case-based panel webinar will discuss the anticipated barriers to the implementation of long-acting injectable preexposure prophylaxis (PrEP), which was approved by the US Food and Drug Administration in December 2021), key aspects of its clinical pharmacology, and the challenges in the diagnosis of HIV in patients on long-acting PrEP.
This webinar is part 2 of a 2-part webinar series on the updated PrEP guidelines. Part 1 provides a summary of the Latest Update to the PrEP Guidelines.
At the end of this webinar, participants will be able to:
- Identify how to address the challenges of implementing long-acting injectable PrEP in the clinic
- Describe how to incorporate long-acting injectable PrEP into clinical practice
- Identify the main drug-drug interactions of long-acting injectable PrEP
- Understand the potential challenges in establishing a diagnosis of HIV in persons using long-acting injectable PrEP
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.
Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Dr Castillo-Mancilla has received grants/grant pending paid to his institution from Gilead Sciences, Inc. (Updated 01/17/22)
Dr Kelley has received grants/grants pending paid to her institution from Moderna, Inc., Novavax, Humanigen, Gilead Sciences, Inc., and ViiV Healthcare. (Updated 02/22/22)
Dr Scarsi has received grant/grants pending paid to her institution from Organon LLC. (Updated 01/28/22)
Dr Scott has no financial relationships with ineligible companies to disclose. (Updated 02/22/22)
Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 02/08/22)
Planner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 02/08/22)
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at email@example.com or 415-544-9400.
How to Claim Credit
- Start the Activity by clicking "START COURSE" located above.
Please note that the "START COURSE" will no longer be visible once you clicked it once.
- Watch the webinar here.
- Return to this page and follow this link to the evaluation form.
- Once you complete the evaluation, you will be directed to the online claim form, where you will record the number of hours that you participated in this activity. You must be logged in to your IAS–USA profile to claim credit. Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
- Your certificate will be available for you to print from your IAS–USA account immediately after you have submitted your claim form. To view your certificates, go to "My Activities" under your profile.